At a glance
ClinicalIndex Comparison RecordPhase 1Terminated· 3 enrolled
Drug / intervention
AlloRxbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Heart Disease
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Dec 7, 2021·Updated Apr 6, 2025
In Brief
A Phase 1 clinical trial evaluating AlloRx for Congestive Heart Failure and Angina. Terminated early, enrolled 3 participants across 2 sites in 2 countries.
Signals
Trial was terminated early
Detailed Summary
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of congestive heart failure and angina
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongestive Heart Failure, Angina
CountriesAntigua and Barbuda, Argentina
Collaborators--
Timeline
Phase 1TerminatedFinished
20222023202420252026
First PostedDec 2021
Enrollment StartFeb 2022
Primary CompletionApr 2025
TodayJul 2026
First PostedDec 7, 2021
Enrollment StartFeb 1, 2022
Primary CompletionApr 3, 2025
TodayJul 1, 2026
Enrollment to primary: 3.2 yearsPosted 4.6 years ago
Interventions
AlloRxbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cells